// App-Quantinova.ai

327 : Prospective evaluation of the response to prednisone-dexamethasone switch in castration-resistant prostate cancer patients treated with abiraterone pre- and post-docetaxel.

Researchers

Presenter

  • Nuria Romero-Laorden

Principal Investigators

  • Elena Castro

  • Rebeca Lozano

  • M Isabel Sez

  • Jeannette Valero

  • Floortje Van de Poll

  • M Paz Nombela

  • Juan Francisco Rodriguez-Moreno

  • A. Montesa

  • Gala Grau

  • Leticia Rivera

  • David Olmos

Medical Centers

  • CNIO - Spanish National Cancer Research Center, Madrid, Spain

  • CNIO - Spanish National Cancer Research Center, Madrid, Spain

  • IBSAL, Servicio Oncología Hospital Universitario de Salamanca, Salamanca, Spain

  • CNIO-IBIMA Genitorurinary Cancer Clinical Research Unit, Hospitales Universitarios Virgen de la Victoria & Regional de Malaga, Malaga, Spain

  • Clara Campal Comprehensive Cancer Center (CIOCC), Madrid, Spain

  • Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • CB-7598

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved